Cancer treatment reports最新文献_第10页

Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study. 绝经后妇女转移性乳腺癌用牛罗莫司汀二线化疗:一项II期研究。

Cancer treatment reports Pub Date : 1987-10-01

P Ernst, I Balslev, H T Mouridsen

引用次数: 0

Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer. 重组β干扰素(ifn - β (ser))在结直肠癌患者中的开放标签II期试验。

Cancer treatment reports Pub Date : 1987-10-01

P L Triozzi, P Kenney, D Young, J J Rinehart

引用次数: 0

Biochemistry of azacitidine: a review. 阿扎胞苷的生物化学研究进展。

Cancer treatment reports Pub Date : 1987-10-01

A B Glover, B Leyland-Jones

引用次数: 0

Limited sampling model for vinblastine pharmacokinetics. 长春花碱药代动力学的有限抽样模型。

Cancer treatment reports Pub Date : 1987-10-01

M J Ratain, N J Vogelzang

引用次数: 0

Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. 每周环磷酰胺和隔日泼尼松:多发性骨髓瘤的有效辅助治疗。

Cancer treatment reports Pub Date : 1987-10-01

K Wilson, W Shelley, A Belch, L Brandes, D Bergsagel, P Klimo, D White, A Willan

引用次数: 0

Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. 连续输注顺铂和5-氟尿嘧啶在结直肠癌中的应用。

Cancer treatment reports Pub Date : 1987-10-01

M R Posner, J F Belliveau, A B Weitberg, K Sabbath, M C Wiemann, F J Cummings, P Calabresi

引用次数: 0

Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. 环磷酰胺、阿霉素和长春新碱在依托泊苷和顺铂耐药小细胞肺癌中的作用。

Cancer treatment reports Pub Date : 1987-10-01

F A Shepherd, W K Evans, R MacCormick, R Feld, J C Yau

{"title":"Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.","authors":"F A Shepherd, W K Evans, R MacCormick, R Feld, J C Yau","doi":"","DOIUrl":"","url":null,"abstract":"For two chemotherapy regimens to be truly non-cross-resistant, each should be active as first-line therapy and also as second-line therapy. The effectiveness of both cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide and cisplatin (VPP) in previously untreated patients with small cell lung cancer has been well-documented. Also, VPP has caused tumor regression in up to 50% of patients when used as second-line therapy after CAV. The effectiveness of CAV after progression or relapse after VPP has not been documented. We identified 29 patients who received CAV after their tumors failed to respond or relapsed after VPP or etoposide and carboplatin (VPC). There were 21 male and eight female patients (median age, 57 years; range, 30-79). Thirteen patients were treated following failure to respond to VPP or VPC and 16 at the time of relapse. Eight patients had limited disease and 21 had extensive disease. Metastatic sites included liver (11 patients), bone (ten), lymph nodes (seven), bone marrow (three), brain (four), and contralateral lung (one). There were three complete responses (durations of 16, 22, and 26 weeks) and five partial responses (duration, 8+ to 36 weeks). Three patients had stable disease and 18 patients had disease progression while receiving treatment. The median survival of the entire group was 15 weeks. Responding patients had a median survival of 34 weeks (range, 8+ to 72+) and stable and nonresponding patients had a survival of only 9 weeks (range, 2-38). A granulocyte count nadir less than 500 X 10(9)/L was seen after 7.9% of evaluable treatment cycles and a platelet count nadir less than 50,000 X 10(9)/L occurred after only 5.3% of cycles. Five patients required transfusion for anemia, and two patients required dose reduction of vincristine for peripheral neuropathy. This study demonstrates that CAV has limited activity following failure to respond to VPP.","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 10","pages":"941-4"},"PeriodicalIF":0.0,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13959048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro. 三种新的雌激素-亚硝基脲偶联物在人乳腺癌细胞系中的雌激素受体结合亲和力和细胞毒活性。

Cancer treatment reports Pub Date : 1987-10-01

H Y Lam, P K Ng, G J Goldenberg, C M Wong

{"title":"Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro.","authors":"H Y Lam, P K Ng, G J Goldenberg, C M Wong","doi":"","DOIUrl":"","url":null,"abstract":"The hypothesis that more selective antitumor activity may be achieved by cytotoxic agents which selectively bind to estrogen receptors (ER) in human cancer cells was tested. We have synthesized three nitrosourea derivatives of estradiol or hexestrol, and compared the ER binding affinity and cytotoxic activity of these compounds against ER-positive and -negative breast cancer cell lines in vitro. Specific binding to ER in the cytosol of MCF-7 human breast cancer cells was demonstrated in these conjugates: 17 alpha-CNU greater than 17 beta-CNU greater than HEX-CNU greater than lomustine (CCNU). The order of cytotoxicity of these derivatives against human breast cancer cells appeared to correlate with their binding affinity to ER. All three estrogen nitrosourea conjugates were more cytotoxic than CCNU, a clinically useful antitumor nitrosourea which does not bind to ER. The contribution of the estrogen moiety to the cytotoxicity of 17 alpha-CNU was demonstrated by the greater activity of the conjugate than that of a combination of estrogen and CCNU. However, cytotoxicity of these compounds against the receptor-positive MCF-7 and receptor-negative Evsa-T human breast cancer cell lines was similar. The latter finding suggested that cytotoxicity of these conjugates may not be mediated through ER. The difference in stability of these nitrosourea conjugates in aqueous buffer may partly explain their differences in cytotoxicity.","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 10","pages":"901-6"},"PeriodicalIF":0.0,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14772264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study. 口服醋酸甲羟孕酮治疗晚期乳腺癌的II期评价:北加州肿瘤组研究。

Cancer treatment reports Pub Date : 1987-10-01

Y O Tan, C Hendrickson, K McWhirter, M Kohler, J F Hannigan, R W Carlson

引用次数: 0

Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents. 表面积计算中的实际重量与理想重量:对11种化疗药物剂量的影响。

Cancer treatment reports Pub Date : 1987-10-01

R S Gelman, D C Tormey, R Betensky, E G Mansour, H C Falkson, G Falkson, R H Creech, D G Haller

{"title":"Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents.","authors":"R S Gelman, D C Tormey, R Betensky, E G Mansour, H C Falkson, G Falkson, R H Creech, D G Haller","doi":"","DOIUrl":"","url":null,"abstract":"This study of 2382 breast, 182 rectal, 817 colon, and 351 lung cancer patients treated with combination chemotherapy on eight phase III Eastern Cooperative Oncology Group protocols indicates that 69% would receive a higher dose of at least one drug if surface area were calculated from actual weight rather than from the minimum of actual and ideal weight. Forty-eight percent of the patients would have at least a 10% increase in drug dose based on actual weight. Only on the premenopausal adjuvant breast cancer protocol and among women on the rectal adjuvant study do the differences in dose based on actual rather than ideal weight increase significantly with age. On the postmenopausal adjuvant breast study and on the lung cancer study, the differences in dose decrease significantly with age. For all age decades and both sexes within each protocol, the mean differences between dose based on actual and dose based on ideal weights were on the same order as the rounding factors for the 11 drugs studied. From the literature on the effect of doses of common chemotherapies on leukopenia, it appears that the percent of hematologic toxicity would not be raised to unacceptable levels by using actual weight to set doses.","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 10","pages":"907-11"},"PeriodicalIF":0.0,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14772265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0